SummaryRMgm-5144
|
||||||||||
*RMgm-5144| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Introduction of a transgene, Introduction of a transgene |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 34959491 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 2.34 |
| Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Hirai M, Mita T |
| Name Group/Department | Department of Tropical Medicine and Parasitology, Faculty of Medicine |
| Name Institute | Juntendo University |
| City | Tokyo |
| Country | Japan |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5144 |
| Principal name | Pb103-AGFP |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | No fluorescent signal in gametocytes. AGFP fluorescent signal was detected from female gametes to ookinetes, while AGFP mRNA was translationally repressed in female gametocytes. |
| Fertilization and ookinete | No fluorescent signal in gametocytes. AGFP fluorescent signal was detected from female gametes to ookinetes, while AGFP mRNA was translationally repressed in female gametocytes. |
| Oocyst | Not tested |
| Sporozoite | Not tested |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Protein (function) Phenotype |
Transgene: Mutant parasite expressing a transgene| top of page | |||||||||||||||||||
| Type and details of transgene | |||||||||||||||||||
| Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
| Transgene name | azami green fluorescent protein (AGFP) | ||||||||||||||||||
| top of page | |||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
| Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
| Additional remarks genetic modification | The pL1186 plasmid was previously designed to make a transgenic line that expresses azami green (AGFP) and red fluorescent proteins (RFPs) for male and female gametocytes to ookinete, respectively. The pL1186 plasmid was digested with EcoRV/NotI and self-ligated to remove the male-specific promoter and AGFP. The resulting plasmid (female-RFP) was digested with two SacII sites and introduced into the 230p gene locus by double-crossover homologous recombination. Subsequently, the transgenic parasite clones were subjected to negative selection using 5-fluorocytosine to remove the selectable marker gene. The resulting parasite clone (female-RFP reporter) expresses RFP throughout female gametocytes to ookinetes [35] and was used as a recipient parasite of the Pb103-AGFP plasmid described below. For the construction of the Pb103-AGFP plasmid, fragments covering the 5' untranslated region (UTR) (1.5 kb) and 3' UTR (1.5 kb) of Pb103 and AGFP were amplified using Pb103-50 UTR-F1/Pb103-50 UTR-R1, Pb103-30 UTR-F1/Pb103-30 UTR-R1, and AGFP-F/AGFP-R. These three fragments were serially cloned in the order of Pb103-50 UTR, AGFP, and Pb103-30 UTR into HindIII/PstIdigested pL0006 by an In-Fusion HD cloning kit (TaKaRa). The final plasmid, Pb103-AGFP, was linearized by the PacI site in the 5' UTR of Pb103 and integrated into the recipient parasites by a single crossover. The final transformant, the Pb103-AGFP reporter, was selected by pyrimethamine. | ||||||||||||||||||
| Additional remarks selection procedure | see above | ||||||||||||||||||
| top of page | |||||||||||||||||||
| Other details transgene | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Promoter | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_1134900 | ||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1358600 | ||||||||||||||||||
| Gene product | zinc finger protein, putative | ||||||||||||||||||
| Gene product: Alternative name | Pb103 | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||
| 3'-UTR | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_1134900 | ||||||||||||||||||
| Gene product | zinc finger protein, putative | ||||||||||||||||||
| Gene product: Alternative name | Pb103 | ||||||||||||||||||
| |||||||||||||||||||
| Insertion/Replacement locus | |||||||||||||||||||
| Replacement / Insertion | Replacement locus | ||||||||||||||||||
| Gene Model of Parasite | PBANKA_1134900 | ||||||||||||||||||
| Gene product | zinc finger protein, putative | ||||||||||||||||||
| Gene product: Alternative name | Pb103 | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||
Transgene: Mutant parasite expressing a transgene| top of page | |||||||||||||||||||
| Type and details of transgene | |||||||||||||||||||
| Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
| Transgene name | RFP | ||||||||||||||||||
| top of page | |||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
| Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
| Additional remarks genetic modification | The pL1186 plasmid was previously designed to make a transgenic line that expresses azami green (AGFP) and red fluorescent proteins (RFPs) for male and female gametocytes to ookinete, respectively. The pL1186 plasmid was digested with EcoRV/NotI and self-ligated to remove the male-specific promoter and AGFP. The resulting plasmid (female-RFP) was digested with two SacII sites and introduced into the 230p gene locus by double-crossover homologous recombination. Subsequently, the transgenic parasite clones were subjected to negative selection using 5-fluorocytosine to remove the selectable marker gene. The resulting parasite clone (female-RFP reporter) expresses RFP throughout female gametocytes to ookinetes [35] and was used as a recipient parasite of the Pb103-AGFP plasmid described below. For the construction of the Pb103-AGFP plasmid, fragments covering the 5' untranslated region (UTR) (1.5 kb) and 3' UTR (1.5 kb) of Pb103 and AGFP were amplified using Pb103-50 UTR-F1/Pb103-50 UTR-R1, Pb103-30 UTR-F1/Pb103-30 UTR-R1, and AGFP-F/AGFP-R. These three fragments were serially cloned in the order of Pb103-50 UTR, AGFP, and Pb103-30 UTR into HindIII/PstIdigested pL0006 by an In-Fusion HD cloning kit (TaKaRa). The final plasmid, Pb103-AGFP, was linearized by the PacI site in the 5' UTR of Pb103 and integrated into the recipient parasites by a single crossover. The final transformant, the Pb103-AGFP reporter, was selected by pyrimethamine. | ||||||||||||||||||
| Additional remarks selection procedure | see above | ||||||||||||||||||
| top of page | |||||||||||||||||||
| Other details transgene | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Promoter | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_1319500 | ||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1455800 | ||||||||||||||||||
| Gene product | LCCL domain-containing protein | ||||||||||||||||||
| Gene product: Alternative name | LAP4; LCCL/lectin adhesive-like protein 4; CCp2 | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||
| 3'-UTR | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_1359600 | ||||||||||||||||||
| Gene product | transmission blocking target antigen precursor 6-cysteine protein | ||||||||||||||||||
| Gene product: Alternative name | P48/45 | ||||||||||||||||||
| |||||||||||||||||||
| Insertion/Replacement locus | |||||||||||||||||||
| Replacement / Insertion | Replacement locus | ||||||||||||||||||
| Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
| Gene product | 6-cysteine protein | ||||||||||||||||||
| Gene product: Alternative name | 230p | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||